Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 7/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879888 | 1.00 | RELA (0.54) | RELARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4881439 | 0.85 | ALOX15 (0.50) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL4881442 | 0.85 | ALOX15 (0.50) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL13264727 | 0.75 | RELA (0.80) | RELARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4879301 | 0.75 | ALOX15 (0.74) | RELARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL1809702 | 0.75 | ALOX15 (0.74) | RELARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4876228 | 0.74 | CYP11B1 (0.57) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL4876221 | 0.74 | CYP11B1 (0.57) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL4651175 | 0.73 | NR4A2 (0.56) | RELARAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL14065982 | 0.73 | NR4A2 (0.56) | RELARAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | claimed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | RELA 4858/4885RAB9A 3960/4885MAPT 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.